[{"orgOrder":0,"company":"Biovectra Inc","sponsor":"PhaseBio Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"","productType":"Large molecule","year":"2021","type":"Agreement","leadProduct":"Bentracimab","moa":"P2Y12 receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Biovectra Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Biovectra Inc \/ PhaseBio Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Biovectra Inc \/ PhaseBio Pharmaceuticals"}]

Find Clinical Drug Pipeline Developments & Deals by Biovectra Inc

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : BioVectra will provide its integrated CDMO services for the manufacturing of the active pharmaceutical ingredient (API) of bentracimab for use in PhaseBio’s ongoing global clinical trials and for global commercial use upon regulatory approval.

                          Brand Name : PB2452

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          March 11, 2021

                          Lead Product(s) : Bentracimab

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase III

                          Sponsor : PhaseBio Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank